Literature DB >> 18809617

Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10.

Andrea Bezjak1, Christopher W Lee, Keyue Ding, Michael Brundage, Timothy Winton, Barbara Graham, Marlo Whitehead, David H Johnson, Robert B Livingston, Lesley Seymour, Frances A Shepherd.   

Abstract

PURPOSE: Adjuvant chemotherapy for early stage non-small-cell lung cancer (NSCLC) is now the standard of care, but there is little information regarding its impact on quality of life (QOL). We report the QOL results of JBR.10, a North American, intergroup, randomized trial of adjuvant cisplatin and vinorelbine compared with observation in patients who have completely resected, stages IB to II NSCLC. PATIENTS AND METHODS: QOL was assessed with the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 and a trial-specific checklist at baseline and at weeks 5 and 9 for those who received chemotherapy and at follow-up months 3, 6, 9, 12, 18, 24, 30 and 36. A 10-point change in QOL scores from baseline was considered clinically significant.
RESULTS: Four hundred eighty-two patients were randomly assigned on JBR.10. A total of 173 patients (82% of the expected) in the observation arm and 186 (85% of expected) in the chemotherapy arm completed baseline QOL assessments. The two groups were comparable, with low global QOL scores and significant symptom burden, especially pain and fatigue, after thoracotomy. Changes in QOL during chemotherapy were relatively modest; fatigue, nausea, and vomiting worsened, but there was a reduction in pain and no change in global QOL. Patients in the observation arm showed considerable improvements in QOL by 3 months. QOL, except for symptoms of sensory neuropathy and hearing loss, in those treated with chemotherapy returned to baseline by 9 months.
CONCLUSION: The findings of this trial indicate that the negative effects of adjuvant chemotherapy on QOL appear to be temporary, and that improvements (with a return to baseline function) are likely in most patients.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18809617      PMCID: PMC2652099          DOI: 10.1200/JCO.2007.12.6094

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  39 in total

1.  Adjuvant chemotherapy for lung cancer--a new standard of care.

Authors:  Ronald H Blum
Journal:  N Engl J Med       Date:  2004-01-22       Impact factor: 91.245

Review 2.  Outcomes research in lung cancer.

Authors:  Craig C Earle
Journal:  J Natl Cancer Inst Monogr       Date:  2004

3.  Response shift in the perception of health for utility evaluation. an explorative investigation.

Authors:  J Bernhard; A Lowy; R Maibach; C Hürny
Journal:  Eur J Cancer       Date:  2001-09       Impact factor: 9.162

4.  Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group.

Authors:  Cesare Gridelli; Ciro Gallo; Frances A Shepherd; Alfonso Illiano; Francovito Piantedosi; Sergio Federico Robbiati; Luigi Manzione; Santi Barbera; Luciano Frontini; Enzo Veltri; Brian Findlay; Silvio Cigolari; Robert Myers; Giovanni P Ianniello; Vittorio Gebbia; Giampietro Gasparini; Sergio Fava; Vera Hirsh; Andrea Bezjak; Lesley Seymour; Francesco Perrone
Journal:  J Clin Oncol       Date:  2003-07-01       Impact factor: 44.544

5.  Quality of life following lung cancer resection: video-assisted thoracic surgery vs thoracotomy.

Authors:  Wilson W L Li; T W Lee; Shirley S Y Lam; Calvin S H Ng; Alan D L Sihoe; Innes Y P Wan; Anthony P C Yim
Journal:  Chest       Date:  2002-08       Impact factor: 9.410

6.  Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

Authors:  Rodrigo Arriagada; Bengt Bergman; Ariane Dunant; Thierry Le Chevalier; Jean-Pierre Pignon; Johan Vansteenkiste
Journal:  N Engl J Med       Date:  2004-01-22       Impact factor: 91.245

7.  Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer.

Authors:  M L G Janssen-Heijnen; S Smulders; V E P P Lemmens; F W J M Smeenk; H J A A van Geffen; J W W Coebergh
Journal:  Thorax       Date:  2004-07       Impact factor: 9.139

8.  Impact of comorbidity on lung cancer survival.

Authors:  C Martin Tammemagi; Christine Neslund-Dudas; Michael Simoff; Paul Kvale
Journal:  Int J Cancer       Date:  2003-03-01       Impact factor: 7.396

9.  What happens to patients undergoing lung cancer surgery? Outcomes and quality of life before and after surgery.

Authors:  John R Handy; James W Asaph; Laurie Skokan; Carolyn E Reed; Sydney Koh; Gladney Brooks; E Charles Douville; Andrew C Tsen; Gary Y Ott; Gerard A Silvestri
Journal:  Chest       Date:  2002-07       Impact factor: 9.410

10.  Supportive care in patients with advanced non-small-cell lung cancer.

Authors:  M Di Maio; F Perrone; C Gallo; R V Iaffaioli; L Manzione; F V Piantedosi; S Cigolari; A Illiano; S Barbera; S F Robbiati; E Piazza; G P Ianniello; L Frontini; E Veltri; F Castiglione; F Rosetti; E De Maio; P Maione; C Gridelli; Antonio Rossi; Emiddio Barletta; Maria Luisa Barzelloni; Giuseppe Signoriello; Domenico Bilancia; Angela Dinota; Gerardo Rosati; Domenico Germano; Alfredo Lamberti; Vittorio Pontillo; Luigi Brancacio; Carlo Crispino; Maria Esposito; Ciro Battiloro; Giovanni Tufano; Angela Cioffi; Vincenzo Guardasole; Valentina Angelini; Giovanna Guidetti; Santi Barbera; Francesco Renda; Francesco Romano; Antonio Volpintesta; Sergio Federico Robbiati; Mirella Sannicolò; Virginio Filipazzi; Gabriella Esani; Anna Gambaro; Sabrina Ferrario; Vincenza Tinessa; Maria Grazia Caprio; Sabrina Zonato; Mary Cabiddu; Alberto Raina; Enzo Veltri; Modesto D'Aprile; Giorgio Pistillucci; Gianfranco Porcile; Oliviero Ostellino; Orazio Vinante; Giuseppe Azzarello; Vittorio Gebbia; Nicola Borsellino; Antonio Testa; Giampietro Gasparini; Alessandra Morabito; Domenico Gattuso; Sante Romito; Francesco Carrozza; Sergio Fava; Anna Calcagno; Emanuela Grimi; Oscar Bertetto; Libero Ciuffreda; Giuseppe Parello; Luigi Maiorino; Antonio Santoro; Massimiliano Santoro; Giuseppe Failla; Rosa Anna Aiello; Alessandra Bearz; Roberto Sorio; Simona Scalone; Maurizia Clerici; Roberto Bollina; Paolo Belloni; Cosimo Sacco; Angela Sibau; Vincenzo Adamo; Giuseppe Altavilla; Antonino Scimone; Mario Spatafora; Vincenzo Bellia; Maria Raffealla Hopps; Silvio Monfardini; Adolfo Favaretto; Micaela Stefani; Giuliana Mara Corradini; Gianfranco Pavia; Giorgio Scagliotti; Silvia Novello; Giovanni Selvaggi; Maurizio Tonato; Samir Darwish; Giovanni Michetti; Maria Ori Belometti; Roberto Labianca; Antonello Quadri; Filippo De Marinis; Maria Rita Migliorino; Olga Martelli; Giuseppe Colucci; Dominico Galetta; Francesco Giotta; Luciano Isa; Paola Candido; Nestore Rossi; Antonio Calandriello; Francesco Ferraù; Emilia Malaponte; Sandro Barni; Marina Cazzaniga; Nicola Gebbia; Maria Rosaria Valerio; Mario Belli; Giuseppe Colantuoni; Matteo Antonio Capuano; Michele Angiolillo; Francesco Sollitto; Antonio Ardizzoia; Gino Luporini; Maria Cristina Locatelli; Franca Pari; Enrico Aitini; Tonino Pedicini; Antonio Febbraro; Cesira Zollo; Francesco Di Costanzo; Roberta Bartolucci; Silvia Gasperoni; Fernando Gaion; Giovanni Palazzolo; Enzo Galligioni; Orazio Caffo; Enrico Cortesi; Giuliana D'Auria; Carlo Curcio; Matteo Vasta; Cesare Bumma; Alfredo Celano; Sergio Bretti; Giuseppe Nettis; Annamaria Anselmo; Rodolfo Mattioli; Cecilia Nisticò; Annamaria Aschelter; Paola Foa
Journal:  Br J Cancer       Date:  2003-09-15       Impact factor: 7.640

View more
  24 in total

Review 1.  Adjuvant chemotherapy in non-small cell lung cancer: state-of-the-art.

Authors:  Ángel Artal Cortés; Lourdes Calera Urquizu; Jorge Hernando Cubero
Journal:  Transl Lung Cancer Res       Date:  2015-04

Review 2.  Adjuvant therapy in non-small cell lung cancer: current and future directions.

Authors:  Randeep Sangha; Julie Price; Charles A Butts
Journal:  Oncologist       Date:  2010-08-03

Review 3.  Survivorship in Non-Small Cell Lung Cancer: Challenges Faced and Steps Forward.

Authors:  Namrata Vijayvergia; Prashant C Shah; Crystal S Denlinger
Journal:  J Natl Compr Canc Netw       Date:  2015-09       Impact factor: 11.908

Review 4.  Metrics to assess quality of life after management of early-stage lung cancer.

Authors:  Jeff A Sloan
Journal:  Cancer J       Date:  2011 Jan-Feb       Impact factor: 3.360

5.  Quality-adjusted time without symptoms or toxicity analysis of adjuvant chemotherapy in non-small-cell lung cancer: an analysis of the National Cancer Institute of Canada Clinical Trials Group JBR.10 trial.

Authors:  Raymond W Jang; Aurélie Le Maître; Keyue Ding; Tim Winton; Andrea Bezjak; Lesley Seymour; Frances A Shepherd; Natasha B Leighl
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

6.  Development and validation of a quantitative real-time polymerase chain reaction classifier for lung cancer prognosis.

Authors:  Guoan Chen; Sinae Kim; Jeremy M G Taylor; Zhuwen Wang; Oliver Lee; Nithya Ramnath; Rishindra M Reddy; Jules Lin; Andrew C Chang; Mark B Orringer; David G Beer
Journal:  J Thorac Oncol       Date:  2011-09       Impact factor: 15.609

Review 7.  Health-related quality of life in non-small-cell lung cancer: an update of a systematic review on methodologic issues in randomized controlled trials.

Authors:  Lily Claassens; Jan van Meerbeeck; Corneel Coens; Chantal Quinten; Irina Ghislain; Elizabeth K Sloan; Xin Shelly Wang; Galina Velikova; Andrew Bottomley
Journal:  J Clin Oncol       Date:  2011-04-04       Impact factor: 44.544

Review 8.  Adjuvant chemotherapy of completely resected early stage non-small cell lung cancer (NSCLC).

Authors:  Ying Liang; Heather A Wakelee
Journal:  Transl Lung Cancer Res       Date:  2013-10

Review 9.  Long-Term and Latent Side Effects of Specific Cancer Types.

Authors:  Nana Gegechkori; Lindsay Haines; Jenny J Lin
Journal:  Med Clin North Am       Date:  2017-08-02       Impact factor: 5.456

10.  Effects of curative-intent lung cancer therapy on functional exercise capacity and patient-reported outcomes.

Authors:  Duc Ha; Andrew L Ries; Scott M Lippman; Mark M Fuster
Journal:  Support Care Cancer       Date:  2020-01-21       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.